<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01034865</url>
  </required_header>
  <id_info>
    <org_study_id>SU-11022007-788</org_study_id>
    <secondary_id>76873</secondary_id>
    <secondary_id>HEP0009</secondary_id>
    <nct_id>NCT01034865</nct_id>
  </id_info>
  <brief_title>Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer</brief_title>
  <official_title>Risk Factors and Molecular Genomics for Hepatocellular Carcinoma in U.S. Patients With Chronic Liver Disease: A Case Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      To identify risk factors for the development and diagnosis of hepatocellular CA in patients
      with chronic hepatitis C and to use the data to ultimately develop an effective screening
      program.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">750</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>HCC PTS</arm_group_label>
    <description>Patients with HCC with either: (i) a hepatic mass larger or equal to 5cm, or; (ii) a hepatic mass lesion confirmed by fine needle aspirate (FNA) or by pathology in the cases of surgical resection, or; (iii) a hepatic mass lesion with characteristic CT or MRI or angiographic appearance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LD</arm_group_label>
    <description>Patients with chronic liver disease without evidence of HCC</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        For Experimental Subjects Only:

        Patients with HCC

        For Controls Only:

        Patients with chronic liver disease without evidence of HCC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For both experimental subjects and controls:

               1. Patients between older than 18 years of age of all ethnic backgrounds and
                  genders.

               2. Patients with chronic liver disease

          -  For Experimental Subjects Only:

               1. Patients with HCC with a hepatic mass larger or equal to 5cm

               2. Patients with HCC with a hepatic mass lesion confirmed by fine needle aspirate
                  (FNA) or by pathology in the cases of surgical resection

               3. Patients with HCC with a hepatic mass lesion with characteristic CT or MRI or
                  angiographic appearance.

          -  For Controls Only:

        Patients with chronic liver disease without evidence of HCC confirmed by either :

        1. A normal AFP level

        2. a negative imaging study (ultrasound, CT, or MR imaging).

        3. Negative liver cancer on explants.

        *Exclusion Criteria:

          1. Patients who declined to participate in the study

          2. Patients with a history of HIV infection

          3. Patients with concurrent advanced malignancy of non-hepatic origin.

          4. Patients with significant use of androgenic steroid.

          5. Patients with exposure to vinyl chloride.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mindie H. Nguyen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2009</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Mindie H. Nguyen</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

